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BACKGROUND
Stuttering, a condition in which the normal pattern, rhythm, or timing of speech is disrupted, may be characterized by repetition and prolongation of words, phrases, and sounds, as well as hesitations or pauses that interrupt speech fl ow. Causes may be developmental (occurring in childhood), neurogenic (eg, head injury, stroke), or psychogenic (related to emotional trauma or stress). Because mild stuttering is often self-limiting, it is rarely treated. Patients with more severe forms often require speech therapy and counseling. Pharmacological therapy has produced inconsistent results or has been limited by side effects. 1, 2 It has been suggested that an antidopaminergic effect may be benefi cial in reversing stuttering problems. 3 Risperidone, an antipsychotic approved for various psychiatric disorders, has broad neurotransmitter activity including antidopaminergic action and may be useful in resolving stuttering.
PATIENT POPULATION
Adult patients with developmental stuttering.
DOSAGE AND DURATION
Dosage range is 0.5 mg to 2 mg daily. Initial dosing may begin as 0.5 mg nightly, increased by 0.5 mg daily every 4 days or more as tolerated to a maximum of 2 mg daily.
SCALES
The Stuttering Severity Instrument for Children and Adults -Third Edition (SSI-3) is an objective measurement of overall stuttering severity via analysis of an audio/videotape of the subject speaking 200 to 500 words of standardized conversation and reading tasks randomly assigned. The assessment incorporates ratings of the percent syllables stuttered of syllables spoken, the duration of stuttering events, and the physical concomitants of stuttering behavior (eg, associated struggle, tic motions).
RESULTS
The evaluation of risperidone in the management of developmental stuttering is limited to small controlled trials and case report data, enrolling less than a total of 50 patients and demonstrating benefi cial effects in several scale measurements of stuttering.
Controlled Trials
Risperidone has been studied in 2 small controlled trials for the management of developmental stuttering in adults. 4, 5 Both studies were performed by the same investigator group. In a 6-week, double-blind, placebo-controlled trial, 16 adult patients with developmental stuttering (onset prior to 6 years of age) and a minimum SSI-3 score of 15 were randomized
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to receive either risperidone 0.5 mg nightly titrated to 2 mg nightly or placebo. When compared with baseline, there were signifi cant improvements in the risperidone group for most scale measurements, including the mean SSI-3 score (25.3 vs 17.5; P < .001), the percentage of syllables stuttered (%SS; 9.6% vs 4.7%; P < .01), and the time spent stuttering as a percentage of total time speaking (%TS; 28% vs 16.7%; P < .01). The duration of stuttering was unaffected (4.5 vs 3.2 seconds). In contrast, there were no signifi cant changes in the placebo group for the same measurements from baseline to the end of the study period. 4 In a similar 6-week study design, 21 adults with developmental stuttering (onset prior to 6 years of age) were randomized to receive risperidone (same dose as above study) or placebo. When compared with placebo, risperidone signifi cantly improved mean SSI-3 scores (3.93 vs 5.23; P < 0.05) but not the %TS (4.75% vs 4.41%). 5
Case Reports
Two case reports described the benefi cial effects associated with risperidone treatment in persistent developmental stuttering. Both adult patients (ages 42 and 24 years) experienced signifi cant reductions in tic-like motor behaviors and linguistic dysfl uencies after risperidone therapy was initiated. Dosages ranged from 0.5 mg to 2 mg daily. 6, 7 
SAFETY
This is a limited safety profi le. Refer to package labeling for complete prescribing information (eg, Warnings/Precautions, Adverse Reactions, Drug Interactions).
Adverse reactions were reported in only 1 of the controlled trials. 4 The drug was generally well tolerated without evidence of extrapyramidal symptoms. Sedation occurred in 3 patients but was transient and responded to dose reduction. Galactorrhea and amenorrhea occurred in a female patient and persisted when the dose was reduced from 1 to 0.5 mg daily. The patient completed the trial, and the symptoms reversed within 2 months of drug discontinuation. Risperidone-induced stuttering has been reported in a limited number of case reports describing adult patients receiving 4 mg daily. 8, 9 Risperidone product labeling contains a boxed warning regarding an increased mortality in elderly patients with dementia-related psychosis. 10
THERAPY CONSIDERATIONS
The use of risperidone in the management of developmental stuttering is limited to small controlled trials and case report data and demonstrates benefi cial effects. This drug may be a therapeutic option in the management of stuttering in adults, but it requires further evaluation in larger controlled trials.
